Vizsgálati helyszín
Changsha
Changsha, Hunan 410013, KínaMég nincs intézményhez kötve
- 15futó vizsgálat
- 11lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 26 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis16 vizsgálat
- 2. fázis5 vizsgálat
- 1/2. fázis1 vizsgálat
- 4. fázis1 vizsgálat
- Állapot
- Fut, nem toboroz15 vizsgálat
- Lezárult9 vizsgálat
- Leállították2 vizsgálat
- Fő szponzor
- Novartis Pharmaceuticals26 vizsgálat
Futó vizsgálatok
Fut, nem toboroz
Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments
NCT07468071· 1/2. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
NCT07517263· 3. fázis· Novartis Pharmaceuticals· Forrás
Toboroz
Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
NCT06947993· 2. fázis· Novartis Pharmaceuticals· Forrás
Contact: Novartis Pharmaceuticals
Fut, nem toboroz
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)
NCT06799000· 3. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.
NCT06517758· 3. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
NCT05739383· 3. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.
NCT05445843· 2. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis
NCT05126277· 3. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
Roll-over Study to Allow Continued Access to Ribociclib
NCT05161195· 4. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1)
NCT05147220· 3. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease
NCT05030428· 3. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer
NCT04940052· 3. fázis· Novartis Pharmaceuticals· Forrás
Toboroz
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
NCT04557462· 3. fázis· Novartis Pharmaceuticals· Forrás
Contact: Novartis Pharmaceuticals
Fut, nem toboroz
Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer
NCT04544189· 2. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
Effectiveness and Safety of Dabrafenib in Combination With Trametinib as Adjuvant Treatment for Chinese Patients With Stage III BRAF V600 Mutation-positive Melanoma After Complete Resection
NCT04666272· Novartis Pharmaceuticals· Forrás
Hibát jelzek